Holen Sie sich die Stockscreener-App
1.33
2.21%
-0.03
Handel nachbörslich:
1.34
0.01
+0.75%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LXRX?
Forum
Prognose
Aktiensplit
Lexicon Pharmaceuticals Inc Aktie (LXRX) Neueste Nachrichten
Lexicon (NASDAQ: LXRX) to present sotagliflozin data in HFpEF, HCM, and T2D at AHA 2025 - Stock Titan
What MACD signals say about Lexicon Pharmaceuticals Inc.Earnings Overview Summary & Fast Momentum Stock Entry Tips - newser.com
What the charts say about Lexicon Pharmaceuticals Inc. today2025 Price Action Summary & Weekly Market Pulse Alerts - newser.com
Applying Wyckoff theory to Lexicon Pharmaceuticals Inc. stockGlobal Markets & Free Reliable Trade Execution Plans - newser.com
Why Lexicon Pharmaceuticals Inc. stock remains a top recommendation2025 Top Gainers & Daily Chart Pattern Signal Reports - newser.com
Is Lexicon Pharmaceuticals Inc. stock attractive for growth ETFsJuly 2025 Setups & Accurate Trade Setup Notifications - newser.com
Published on: 2025-11-02 14:31:16 - newser.com
What candlestick patterns are forming on Lexicon Pharmaceuticals Inc.2025 Big Picture & Safe Entry Zone Identification - newser.com
Using data tools to time your Lexicon Pharmaceuticals Inc. exitQuarterly Market Review & Real-Time Sentiment Analysis - newser.com
Is Lexicon Pharmaceuticals Inc. stock attractive for hedge fundsQuarterly Growth Report & Verified Trade Idea Suggestions - newser.com
Published on: 2025-10-31 04:02:24 - newser.com
Lexicon Pharmaceuticals, Inc. (LXRX) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 - The Manila Times
Lexicon (NASDAQ: LXRX) sets Nov. 6 call for third quarter results at 8:30 a.m. ET - Stock Titan
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2024 Earnings Call Transcript - MSN
How analysts rate Lexicon Pharmaceuticals Inc. stock todayLayoff News & Free Real-Time Volume Trigger Notifications - Fundação Cultural do Pará
Is Lexicon Pharmaceuticals Inc. stock a defensive play in 2025Weekly Earnings Recap & Free Accurate Trade Setup Notifications - fcp.pa.gov.br
Weiss Ratings Reaffirms "Sell (D-)" Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - MarketBeat
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):